Nektar Hit With Derivative Suit Over Drug Trial Results
Nektar Therapeutics was hit Wednesday with a stockholder derivative suit in Delaware federal court alleging the pharmaceutical company's executives misled shareholders about the experimental results of its leading cancer drug and...To view the full article, register now.
Already a subscriber? Click here to view full article